Cyanidin-3-O-arabinoside
Based on 1 publication(s) in Google Scholar
Cyanidin-3-O-arabinoside is a p38 MAPK phosphorylation inhibitor. Cyanidin-3-O-arabinoside reduces the expression of VDAC1, inhibits mtROS accumulation, reverses cellular senescence, blocks excessive mitochondrial calcium influx, reduces the formation of mitochondria-associated endoplasmic reticulum membranes, and suppresses the VDAC1-IP3R1 interaction. Cyanidin-3-O-arabinoside activates hair follicle stem cell proliferation and improves the condition of slowed hair growth. Cyanidin-3-O-arabinoside is applicable to research related to colon cancer and androgenetic alopecia.
For research use only. We do not sell to patients.
- Purity: 95.71%
- CAS No.: 111613-04-8
- Formula: C20H19ClO10
- Molecular Weight:454.81
-
Storage:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Cyanidin-3-O-arabinoside
More
Biological Activity
|
VDAC1 |
IL-6 |
Cyanidin-3-O-arabinoside exhibits strong binding affinity with purified human APN, JAK3 and EZH2 proteins[1].
Cyanidin-3-O-arabinoside (120-320 μg/mL; 24-72 h) potently inhibits the proliferation of Caco-2 cells in a concentration- and time-dependent manner[1].
Cyanidin-3-O-arabinoside (120-280 μg/mL; 72 h) induces concentration-dependent apoptosis and cell cycle arrest in Caco-2 cells, and increases the accumulation of cells in the G0/G1 phase[1].
Cyanidin-3-O-arabinoside (120-280 μg/mL; 72 h) exerts a concentration-dependent regulatory effect on apoptosis-related proteins in Caco-2 cells, upregulating the expression of Bax and downregulating the expression of Bcl-2 after 72 h of treatment[1].
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 72 h co-incubation with DHT) reverses dihydrotestosterone (DHT)-induced senescence in human dermal papilla cells (DPCs) by reducing the number of SA-β-gal-positive cells and inhibiting the expression of senescence markers (p21, p16)[2].
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 48 h co-incubation with DHT) effectively reduces dihydrotestosterone (DHT)-induced mtROS accumulation in human dermal papilla cells (DPCs)[2].
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 2 h co-incubation with DHT) inhibits dihydrotestosterone (DHT)-induced reactive oxygen species (ROS) production in human dermal papilla cells (DPCs)[2].
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 48 h co-incubation with DHT) blocks dihydrotestosterone (DHT)-induced excessive mitochondrial calcium accumulation in human dermal papilla cells (DPCs)[2].
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 24 h co-incubation with DHT) reduces dihydrotestosterone (DHT)-induced formation of mitochondria-associated endoplasmic reticulum membranes (MAM) in human dermal papilla cells (DPCs) by inhibiting VDAC1 expression and the VDAC1-IP3R1 interaction[2].
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, co-incubation with DHT) inhibits dihydrotestosterone (DHT)-induced AR transcriptional activity in human dermal papilla cells (DPCs)[2].
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 72 h co-incubation with DHT for DPCs). Pretreatment of human dermal papilla cells (DPCs) exposed to dihydrotestosterone (DHT) with this medium restores the proliferation of human hair follicle stem cells (HFSCs) and reduces the expression of HFSC senescence markers[2].
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 24 h co-incubation with DHT for qPCR, 72 h co-incubation with DHT for ELISA) reverses the dihydrotestosterone (DHT)-induced upregulation of hair follicle regulators (DKK1, TGFB1, IL6) at both mRNA and protein levels in human dermal papilla cells (DPCs)[2].
Cyanidin-3-O-arabinoside (1 μM; 30 min pre-incubation, 2 h co-incubation with DHT) inhibits dihydrotestosterone (DHT)-induced phosphorylation of p38 mitogen-activated protein kinase (MAPK) and subsequent phosphorylation of HSP27 in human dermal papilla cells (DPCs)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human colon adenocarcinoma Caco-2 cells
-
Concentration:120, 160, 200, 240, 280, 320 μg/mL
-
Incubation Time:24, 48, 72 h
-
Result:Inhibited Caco-2 cell proliferation in a concentration- and time-dependent manner.
Achieved an inhibition rate of 93.5% at 72 h with 320 μg/mL.
Exhibited IC50 values of 227, 124, and 112 μg/mL for 24, 48, and 72 h treatments, respectively.
-
Cell Line:human colon adenocarcinoma Caco-2 cells
-
Concentration:120, 160, 200, 240, 280 μg/mL
-
Incubation Time:72 h
-
Result:Induced Caco-2 cell apoptosis in a concentration-dependent manner.
Increased the proportion of late apoptotic cells from 1.3% (untreated) to 40.7% at 280 μg/mL.
Reached a total apoptosis rate of 50% at 280 μg/mL.
-
Cell Line:human colon adenocarcinoma Caco-2 cells
-
Concentration:120, 160, 200, 240, 280 μg/mL
-
Incubation Time:72 h
-
Result:Altered Caco-2 cell cycle distribution in a concentration-dependent manner.
Increased the proportion of cells in G0/G1 phase from 45.1% (untreated) to 73.5% at 280 μg/mL.
Decreased the proportion of cells in S phase from 37.3% (untreated) to 17.3% at 280 μg/mL.
-
Cell Line:human colon adenocarcinoma Caco-2 cells
-
Concentration:120, 160, 200, 240, 280 μg/mL
-
Incubation Time:72 h
-
Result:Regulated Bcl-2 and Bax protein expression in a concentration-dependent manner.
Increased Bax expression with higher cyanidin-3-O-arabinoside concentrations.
Decreased Bcl-2 expression with higher cyanidin-3-O-arabinoside concentrations.
-
Cell Line:human dermal papilla cells (DPCs), human hair follicle stem cells (HFSCs)
-
Concentration:1 μM
-
Incubation Time:30 min (pre-incubation); 72 h (co-incubation with DHT for DPCs); 48 h (HFSC culture with conditioned media)
-
Result:Reduced the deleterious effect of DHT-treated DPC-conditioned media on HFSC proliferation.
Reversed DHT-induced downregulation of FGF4 and FGF6 in DPC-conditioned media.
Decreased senescence marker (p16, p21) expression in HFSCs exposed to DHT-treated conditioned media.
-
Cell Line:human dermal papilla cells (DPCs)
-
Concentration:1 μM
-
Incubation Time:30 min (pre-incubation); 2 h (co-incubation with DHT)
-
Result:Reduced DHT-induced phosphorylation of p38, while not significantly affecting phosphorylation of ERK or JNK.
Reversed DHT-induced phosphorylation of HSP27.
-
Cell Line:human dermal papilla cells (DPCs)
-
Concentration:1 μM
-
Incubation Time:24 h co-incubation with DHT
-
Result:Reversed dihydrotestosterone (DHT)-induced upregulation of hair follicle-regulatory factors (DKK1, TGFB1, IL6) in human dermal papilla cells (DPCs) at both mRNA and protein levels.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (7-week-old male, androgenetic alopecia model via DHT injection + shaving/depilation)[2]
-
Dosage:500 μM
-
Administration:topical; once every 2 days; 19 days
-
Result:Restored DHT-induced hair growth deceleration.
Reversed DHT-induced reduction in hair bulb diameter, skin thickness, and dermal ratio to levels comparable to non-DHT treated control mice.
Increased normalized fluorescence intensity of Ki67 in hair follicle regions, reversing DHT-induced reduction in Ki67 signal.
Chemical Information
-
CAS No. 111613-04-8
-
Appearance Solid
-
Molecular Weight 454.81
-
Formula C20H19ClO10
-
Color Brown to black
-
SMILES
OC1=CC2=[O+]C(C3=CC=C(O)C(O)=C3)=C(O[C@H]4[C@@H]([C@H]([C@H](CO4)O)O)O)C=C2C(O)=C1.[Cl-]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 Oct 15:489:144992. PMID: 40466530
Solvent & Solubility
Ethanol : 4.5 mg/mL (9.89 mM; Need ultrasonic and warming)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (290 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol | 1 mM | 2.1987 mL | 10.9936 mL | 21.9872 mL | 54.9680 mL |
| 5 mM | 0.4397 mL | 2.1987 mL | 4.3974 mL | 10.9936 mL |